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Summary: Aspects of osteoporosis in men, such as screening and identiﬁcation strategies, deﬁnitions of diag-
nosis and intervention thresholds, and treatment options (both approved and in the pipeline) are discussed.
Introduction: Awareness of osteoporosis in men is improving, although it remains under-diagnosed and
under-treated. A European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis
(ESCEO) workshop was convened to discuss osteoporosis in men and to provide a report by a panel of experts
(the authors).
Methods: A debate with an expert panel on preselected topics was conducted.
Results and conclusions: Although additional fracture data are needed to endorse the clinical care of osteoporosis
inmen, consensus views were reached on diagnostic criteria and intervention thresholds. Empirical data inmen
display similarities with data acquired in women, despite pathophysiological differences, which may not be
clinically relevant. Men should receive treatment at a similar 10-year fracture probability as in women. The
design ofmixed studiesmay reduce the lag between comparable treatments for osteoporosis inwomen becoming
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Considerable progress has been made in understanding the patho-
physiology and management of osteoporosis, though it remains
under-diagnosed and under-treated [1], particularly in men [2]. Osteo-
porosis is widely considered to be much more prevalent in women,
even though approximately 39% of new osteoporotic fractures estimated
to have occurred worldwide in 2000 were in men [3]. Though the aver-
age age at which osteoporotic fractures occur in men is approximately
5–10 years later than in women depending on fracture type [4], men
have greater morbidity and mortality rates due to hip fractures com-
pared with women [5,6]. There is some lack of awareness among
healthcare providers of the need to evaluate men for osteoporosis [7].
Among patients who have sustained a fragility fracture, men and
women have a similar relative risk (RR) of sustaining a subsequent frac-
ture [8,9], butmen are less likely thanwomen to receive therapy [10,11].
Treatment rates are very low in men (b10%), even in those with a prior
fragility fracture. Moreover, the economic burden of osteoporosis is
expected to rise due to ageing populations [12,13].
Progress has been made in the identiﬁcation of men who should
beneﬁt from treatment (e.g. the FRAX management algorithm is appli-
cable to men). However, controversies remain, for instance regarding
the criteria by which to deﬁne osteoporosis in men on the basis of
bone mineral density (BMD). Most information on osteoporosis is in
women, and most treatments are developed and approved for use in
women. Approved drugs in the US and Europe for osteoporosis treat-
ment in men include bisphosphonates (alendronate, risedronate and
zoledronic acid), and teriparatide. Strontium ranelate was recently ap-
proved in Europe. Denosumab and other drugs are expected to reach
the market in the near future.
This review provides an overview of osteoporosis in men, avail-
able treatment options and potential future approaches to treatment.Osteoporosis in men: is it different from postmenopausal
osteoporosis?
Epidemiology of fractures
In untreated osteoporosis patients, lowBMD is consistently associated
with an increase in fracture risk. About 4–6% of men over the age of50 years have osteoporosis. Estimates of lifetime fracture risk in
men range from 13 to 25%, which is lower than estimates for
women, who have a lifetime fracture risk of up to 50% [14]. The
lower lifetime fracture probability arises because of a lower
age-speciﬁc fracture incidence and shorter life expectancy inmen com-
pared to women. Studies on the impact of osteoporosis-related fractures
in the United Kingdom have shown that the lifetime risk for hip, spine,
and wrist fractures in women is 14, 28, and 13%, respectively, versus 3,
6, and 2% in men [15], although there is variation in reported incidence
rates from country to country [16]. In Europe, estimates of the 10-year
probability of hip fracture in men and women at the age of 50 range
from 0.1 to 0.6% in men vs. 0.2 to 1.1% in women, and increase with ad-
vancing age [16].
Forearm fractures tend to increase in incidence in white women
between the ages of 45 and 60 years, followed by a plateau or more
attenuated rise thereafter, whereas rates in men commonly remain
low, regardless of increasing age. The incidence of hip fracture in-
creases exponentially with age in both men and women in most re-
gions of the world. Most hip fractures are the result of a fall [17].
Population-based studies of vertebral fracture are difﬁcult to compare,
because of a lack of standardised diagnosticmethods and criteria. Verte-
bral fracture prevalence tends to increase with age among men and
women,with a steeper gradient amongwomen [18] (Fig. 1). Other frac-
tures associated with low trauma also increase in frequency with age
among men, including fractures of the rib, clavicle, proximal humerus
and pelvis. They add to themorbidity and mortality burden of osteopo-
rosis in men.
In Caucasians, geographical variations in hip fracture rate in
women are mirrored by that in men. However, gender ratios are dif-
ferent in Latin America and Asia, with a blunting of female to male in-
cidence ratios, but the rankings of high to low tend to remain
consistent, even outside Europe [19]. Although female and male inci-
dence rates are more approximate for India and China, they are very
similar in terms of their rise with advancing age, and remain lower
than hip fracture rates observed in most European countries
[20,15,21]. In a Swedish study, more than twice as many women
than men aged ≥50 years were hospitalised for hip fractures [22],
and studies have reported higher mortality rates after hip fracture
in men than in women. A Canadian study observed 71% of hip frac-
tures in women and 29% in men, but in-hospital mortality of
women was half that of men (5% and 10%, respectively) [23]. These
Fig. 1. Osteoporotic fractures in men and women: incidence of osteoporotic fractures in men and women.
Adapted from [17].
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health status and post-fracture complications.
Over the last few decades, temporal changes have been reported in
the age-speciﬁc incidence of fractures in men and women. There does
seem to be geographical diversity, particularly in the rate of rise in hip
fracture incidence evident towards the end of the 20th century [18].
Hip fracture rates have now stabilised in some Western populations
and, in some cases even decreased [24]. In contrast, some studies have
suggested that rates are rising in other populations, particularly in Asia
[21,25,26].
Relationship of fracture incidence to BMD
The diagnosis of osteoporosis relies on the quantitative assessment
of BMD, usually by central dual energy X-ray absorptiometry (DXA)
[27]. It was originally deﬁned in postmenopausal women as a BMD
value that is 2.5 standard deviations (SD) or more below the young
female adult mean. The criteria were later broadened to include
men and the femoral neck as the reference site [28] (based on the
Third National Health and Nutrition Examination Survey [NHANES
III] reference population of women aged 20–29 years) [29].
The use of a common reference range arises from several lines of ev-
idence. A World Health Organization (WHO) systematic review and
meta-analysis of data from 12 cohort studies including approximately
39,000 men and women assessed relationship between BMD and frac-
ture risk. The data suggested a consistent increase in the RR of fracture
for each SD decrease in femoral neck BMD. The gradient of risk was
higher for hip fracture than for all osteoporotic fractures, but was the
same in men as in women for both outcomes [8], so that the fracture
risk inmen andwomen at any given agewas similar for a same absolute
BMD value. The same study showed a decreasing gradient of risk for hip
fracture with advancing age, but the age-dependency of fracture risk
was similar inmen andwomen [8]. The systematic review expressed ab-
solute fracture risk as 10-year probability of hip fracture according to age
and BMD T-score and concluded that the age-adjusted hip fracture inci-
dence was identical in men and women of the same age and the same
BMD [8].
Because the relationship between BMD and fracture risk changes
with age [30], several studies investigating fracture risk in men andwomen have reached different conclusions [8,31–36]. However, the
available studies show that the risk of hip and vertebral fracture is similar
in men and women for any given BMD [8,30,35,37–39], supporting the
use of a BMD value of 2.5 SD or more below the mean for young adult
women for the diagnosis of osteoporosis in men.
Clinical risk factors and relationship to BMD
The prevalence of individual risk factors for osteoporotic fracture is
commonly reported to be different inmen compared towomen. It is fre-
quently suggested that osteoporosis in men often has secondary causes,
the most common being corticosteroid use, excessive alcohol use, and
hypogonadism (Table 1). Other causes that are gaining relevance are
due to clinical problems related to hormone ablation for prostate cancer
(discussed below), highly active anti-retroviral therapy in HIV-infected
patients, and immunosuppressive therapy in organ transplanted pa-
tients [2]. Both in men andwomen, age, prior fracture and BMD capture
a substantial proportion of fracture risk with further independent con-
tribution of additional risk factors.
According to the MrOS study, which evaluated predictors of
non-spine fracture in elderlymen after adjusting for BMD, the following
clinical risk factors were identiﬁed: previous fracture, age, a fall in the
past year, use of tricyclic antidepressants, and inability to complete a
walking test. The combination of multiple risk factors and low BMD
was a powerful indicator of fracture risk. The study found that men
who were in the lowest BMD tertile and had three or more clinical
risk factors had a 15-fold greater fracture risk than those with no risk
factors in the highest BMD tertile [40].
Considering osteoporosis in men as distinct from female osteoporo-
sis might bemisconceived. Clinical practice suggests that men are more
often diagnosed with secondary osteoporosis, but there are no relevant
population-based data to support this notion. It is difﬁcult to distinguish
between the multifactorial nature of female vs.male osteoporosis. A re-
cently presented subanalysis of the MrOs cohort evaluated secondary
causes of osteoporosis in subjects that had low BMD vs. those that did
not have low BMD, and most were similar in terms of their risk factors
[41]. It is thus not established that secondary osteoporosis really is
more common in men. Men may be less likely to be referred for bone
densitometry in the absence of speciﬁc risk factors for osteoporosis,
Table 1
Clinical risk factors used for the assessment of fracture probability in men.
Adapted from [50].
o Age
o Sex
o Low BMI (≤19 kg/m2)
o Previous fragility fracture, in particular of the hip, wrist and spine
o Morphometric vertebral fracture
o Parental history of hip fracture
o Current glucocorticoid treatment (>5 mg prednisolone/day or equivalent for
≥3 months)
o Current smoking
o Alcohol intake of ≥3 units/day
o Secondary causes of osteoporosis including: rheumatoid arthritis, untreated
hypogonadism (e.g. bilateral orchidectomy, anorexia nervosa, hypopituitarism),
inﬂammatory bowel disease (e.g. Crohn's disease and ulcerative colitis),
prolonged immobility, organ transplantation, type I diabetes, thyroid disorders,
chronic obstructive pulmonary disease
o Falls
Table 2
Example of management algorithm for the treatment of men in the UK.
Adapted from [49].
Men with a prior fragility fracture should be referred for BMD assessment.
Men aged ≥50 years with clinical risk factors should have fracture probability
assessed using the FRAX tool without measurement of BMD.
Individuals with probabilities of a major osteoporotic fracture below the lower
predeﬁned assessment threshold can be reassured (range of probabilities for BMD
testing according to age, see below). Assessments are recommended every ﬁve years
or less depending on the clinical context.
Individuals with probabilities of a major osteoporotic fracture above the upper
predeﬁned assessment threshold (see below) or with probabilities of a hip
fracture above the upper limit can be treated without a prior BMD evaluation.
Individuals with probabilities of a major osteoporotic fracture within the limits of the
assessment thresholds andwith probabilities of a hip fracture below the limit should
have a BMD test and probabilities recomputed. If probabilities exceed the treatment
threshold, intervention should be considered. Where probabilities fall below the
treatment threshold, assessments are recommended every ﬁve years or less
depending on the clinical context.
Predeﬁned range of 10-year major fracture probabilities for BMD testing and inter-
vention threshold by age:
Age (years) Lower limit Upper limit Intervention threshold
50 5.7 9 7.5
55 7.5 12 10
60 10 14 12.5
65 14 20 15
70 11 25 20
75 14 29 25
80 18 34 30
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for the causes of secondary osteoporosis in men more carefully than in
women.
Biochemical markers of bone turnover
Use of bone formation (serum procollagen type I N propeptide,
sPINP) and bone resorption (serum C-terminal telopeptide of type I
collagen, sCTX) markers are recommended by the International Osteo-
porosis Foundation (IOF) and the International Federation of Clinical
Chemistry and Laboratory Medicine (IFCC) as reference analytes for
bone turnover markers (BTMs) in clinical studies. Levels of BTMs may
predict fracture risk independently from BMD, and may provide data
on treatment response and monitoring, although a stronger evidence
base is needed.
Conﬂicting data on the association of BTMs with bone loss and frac-
ture risk in men have been reported. A study in elderly men observed a
decreased carboxylated serum osteocalcin to total osteocalcin ratio that
was associated with increased subsequent fracture risk [42]. The Dubbo
Osteoporosis Study of elderly men reported increased sCTX associated
with an increased risk of osteoporotic fractures independent of BMD
[43]. Finally, the MrOS cohort demonstrated that biochemical markers
in men were predictive of bone loss in a similar manner as in women.
Hip and non-spine fractures were associated with increased sPINP and
sCTX, but the association no longer held true after adjusting for hip
BMD [44]. On the other hand, the MINOS study found that serum con-
centrations of BTMs were not predictive of fractures [45]. The question
of whether BTMs are predictive of accelerated bone loss or fractures in
the clinical management of osteoporosis in men remains unanswered.
The adoption of international reference standards would help to clarify
uncertainties on their clinical use [46].
Pathophysiology of bone loss
Men have larger bones compared with women, resulting in greater
bone strength.With age, bone sizemay increase inmen by periosteal ap-
position more than in women, thus further increasing the sex difference
in bone size (reviewed in [6]). One of the most noteworthy differences
betweenmale and female osteoporosis concerns bonemicroarchitecture.
The patterns of bone loss in men seem to be different from those in
women. Earlier trabecular loss was measured in men, with cortical loss
starting after the age of 50 years, possibly linked to gonadal steroid
decline (sex steroids are further discussed below) [7,47]. A deﬁciency
in oestrogen or testosterone may be a unifying factor in the pathophys-
iology of the disease.
Men have a higher trabecular bone volume/tissue volume, which
declines at a similar rate to women. Peripheral quantitative computedtomography (CT) demonstrated that men seem to show a relative
preservation of trabecular number, but more trabecular thinning
[7,6], presumed to be secondary to reduced bone formation and cor-
related with indices of reduced bone formation.Management algorithms
FRAX is a computer-based algorithm (http://www.shef.ac.uk/FRAX)
launched in 2008. It calculates fracture probability from clinical risk
factors (Table 1) and patient characteristics (age, weight, height,
etc.) in both men and women. The output of FRAX is the 10-year
probability of a hip fracture and of a major osteoporotic fracture
(hip, clinical spine, humerus or wrist fracture) [48,49]. As is the
case for women, there is presently no generally accepted algorithm
for the management of osteoporosis in men [50], although FRAX is
being increasingly incorporated into practice guidelines. An example
for the UK is provided in Table 2.
Before the advent of FRAX, management algorithms for men were
very similar to those used in postmenopausal women. In the UK, in
the event of a previous fracture, a DXA would be performed or treat-
ment would be considered in the absence of a BMD measurement. In
the absence of a previous fracture, but if other clinical risk factors are
present (Table 1), a DXA should be performed, and the subject
recommended for treatment if their T-score was below −2.5 SD [51].
In other countries, other T-score thresholds have been used [2]. Although
risks that justify treatment vary on a national basis, treatment is widely
recommended in individuals with a prior history of fragility fracture
[50].
Whereas the diagnosis of osteoporosis centres on the assessment of
BMD at the femoral neck using DXA, other sites and validated tech-
niques can be used for fracture prediction. The FRAX clinical risk factors
contribute to fracture risk independently of BMD. The use of these risk
factors in conjunction with BMD improves sensitivity of fracture predic-
tion without adverse effects on speciﬁcity [52]. Thus, the FRAX algorithm
may signiﬁcantly impact clinical practice because it helps identify indi-
viduals at increased risk of fracture, while avoiding unnecessarily treating
patients at low fracture risk.
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in men
Treatment of osteoporosis in men at increased risk of fracture was
ﬁrst included in the latest revision of the European guidelines on the
evaluation of medicinal products in the treatment of osteoporosis [53].
Previous guidelines were only for use in postmenopausal women. The
guidelines state that, for women, an effect in reducing fracture risk
must be demonstrated on both spinal and non-spinal fractures in a
randomised, double-blind, placebo-controlled primary pivotal study
with a minimum duration of two years to be conducted either in
womenwith a BMDT-score below−2.5 SD or inwomenwith prevalent
fracture. Forwomen to be included in a trial, a 10-year fracture probabil-
ity range of 15–20% for spine, 5–7.5% for hip and 10–15% for major
non-vertebral fractures is suggested as a clinically relevant and suitable
inclusion criterion [53]. Of note, US guidance is slightly different
(reviewed in [54]). In future, since the advent of the FRAX approach,
studies may recruit patients with an increased 10-year probability of
fracture, without distinguishing between prevention and treatment.
Therefore, patients with various BMD values (including osteopenia)
may be included in studies, provided their 10-year probability of frac-
ture is increased. The main relevant issues arising from the revised
guideline are summarised below:
• In the case of a new drug that has not previously been investigated
in women, a two-year placebo-controlled study investigating frac-
ture incidence as the primary endpoint is required to develop
drugs for the treatment of osteoporosis in men at increased risk of
fracture. Most compounds to treat osteoporosis in men have been
developed in females. If a chemical entity has already shown efﬁca-
cy (reduced fracture incidence) in women, a separate bridging
study (vs. placebo in males) of the same drug (same formulation,
dose and route of administration) may be carried out, provided
that the duration is at least one year, and that BMD at the lumbar
spine is the primary endpoint. Baseline fracture risk in the male
population should be similar to the fracture risk of the women in-
cluded in the pivotal study. Finally, the magnitude of BMD changes
observed vs. placebo in males should be similar to that observed in
postmenopausal women.
• In themajority of bridging trials that have been performed inmen, the
risk proﬁle of the included studypopulation did notmatch the fracture
risk level in the pivotal trials in postmenopausal women. Moreover,
since men with osteoporosis now have access to different treatment
modalities, it may not be ethical to include men with high fracture
risk in a placebo-controlled bridging study. Because more recent
phase III studies have included women at lower risk than traditional
studies, the data from these studies are more likely to provide a
suitable basis for bridging to a male population with a lower riskTable 3
Overview of studies in men with osteoporosis (approved agents).
Agent N Study duration Main efﬁcacy
Alendronate
10 mg/day
241 2 years o LS-BMD
Risedronate
35 mg qw
284 2 years o Signiﬁca
(4.5%, 95
o Signiﬁca
Zoledronic acid
5 mg once a year
1199 2 years o Morphom
o LS-BMD
o Signiﬁca
Teriparatide
20 or 40 mcg/day
437 Premature termination
(median total exposure 11 months)
o LS-BMD
(pb0.00
o FN-BMD
Strontium ranelate
2 g/day
261 2 years (1 year to main analysis) o LS-BMD
postmen
o Signiﬁca
BMD, bone mineral density; CI, conﬁdence interval; FN, femoral neck; LS, lumbar spine; qw(to avoid bridging from a high-risk female population to a lower-risk
male population).
Treatment of osteoporosis in men: available agents
Bisphosphonates
Bisphosphonates inhibit osteoclastic bone resorption and are the
most widely used drugs in male osteoporosis. Studies of male osteo-
porosis include the evaluation of alendronate, risedronate, and
zoledronic acid, as summarised below (Table 3). These agents are in-
dicated to increase bone mass in men with osteoporosis.
Alendronate
In a two-year double-blind study, Orwoll et al. investigated
10 mg/day of alendronate or placebo in 241 men with osteoporosis
aged 31–87 years (mean age 63 years). The study included men
with femoral neck BMD at least 2 SD and lumbar spine BMD at least
1 SD below the male reference, or with femoral neck BMD at least 1
SD belowmale reference and at least one vertebral deformity or a his-
tory of an osteoporotic fracture. Half of the study population had
established osteoporosis. At baseline, approximately 50% of patients
had already sustained vertebral fractures [55].
Alendronate-treated men showed a similar increase in BMD as
previously reported in postmenopausal women [56,57]. Lumbar
spine BMD increased by 7.1±0.3%, whereas femoral neck BMD in-
creased by 2.5±0.4% [55]. The changes in BMD with alendronate
were not affected by circulating levels of sex steroids (testosterone
and oestradiol). Therefore, treatment and anti-fracture efﬁcacy of
bisphosphonate may potentially be similar in hypogonadal men and
eugonadal men. In less extreme circumstances, this observation re-
mains relevant in normal men whose testosterone levels decrease
with ageing [58].
The alendronate study for the treatment of osteoporosis in men
was a BMD endpoint study, and as such was not powered to deter-
mine anti-fracture efﬁcacy. However, radiographic vertebral, clinical
vertebral and non-vertebral fracture risks were numerically reduced
in alendronate-treated men, without achieving a level of signiﬁcance.
The effect of alendronate on the change in height was signiﬁcant. Men
in the placebo group lost 2.4 mm in height, compared with 0.6 mm in
the alendronate-treated men (p=0.02). These data, although not
conclusive, are consistent with anti-fracture efﬁcacy [55].
Risedronate
A similar two-year BMD endpoint study was performed with
risedronate 35 mg once a week in 284 men with osteoporosis aged
36–84 years (mean age 60) [59]. Men with a femoral neck BMD of at
least 2 SD and lumbar spine BMD at least 1 SD below male referenceoutcomes Reference
increased by 7.1±0.3%, and FN-BMD increased by 2.5±0.4%. [55]
nt increase from baseline to endpoint in LS-BMD vs. placebo
% CI: 3.5–5.6, pb0.001).
nt increases in hip BMD vs. placebo.
[59]
etric VF results showed a 67% reduction in risk of new VF.
increased from 4.7% at six months to 6.1% at two years.
nt increases in LS-BMD vs. placebo.
[65]
increased by 5.9% (20 mcg) and 9.0% (40 mcg) above baseline
1 vs. placebo for both).
increased by 1.5% (20 mcg, p=0.029) and 2.9% (40 mcg, pb0.001).
[69]
increase at 1 year similar to that previously observed in core studies in
opausal women.
nt increase at the femoral neck.
[97]
, once a week; VF, vertebral fracture.
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least 2.5 SD below male reference values were included. At baseline,
35% and 34% of patients had prevalent vertebral fractures in the placebo
and risedronate groups, respectively [59].
The study reported a signiﬁcant increase from baseline to endpoint in
lumbar spine BMD compared with placebo (4.5%, 95% CI: 3.5–5.6,
pb0.001). Signiﬁcant increases in hip BMDwere also observed compared
with placebo. A 40% reduction in type 1 cross-linkedN-telopeptide (NTX)
was observed in risedronate-treatedmen, again similar to reports in post-
menopausal women [60]. This study also showed that the effects on bone
density and on NTX were not affected by circulating testosterone. The
trial was not designed as a fracture-endpoint study; the number of frac-
tureswas small, as expected, because of the sample size and the study de-
sign. No statistically signiﬁcant difference between treatment groups for
the overall incidence of vertebral fractures or clinical fractures was ob-
served. The cumulative incidence of clinical fractures was 7.7% in men
on placebo vs. 4.9% in risedronate-treated men (RR 0.69 [0.25–1.93]).
The positive effects of risedronate in men with osteoporosis were con-
ﬁrmed in an open-label, prospective, match-control trial [61].
Zoledronic acid
Approval of zoledronic acid for use in men was based on ﬁndings
from the HORIZON Recurrent Fracture Trial (RFT), a study involving
508 men and 1619 women with a recent low trauma hip fracture that
had been surgically repaired [62]. In this study, zoledronic acid (as an an-
nual 5 mg infusion) showed a 35% reduced risk of new clinical fractures
in the overall population compared with placebo, and no signiﬁcant
treatment-by-gender interactionwas observed. More recently, an analy-
sis of the subset ofmenparticipating in theHORIZON-RFT conﬁrmed that
the increase in BMD in men was statistically similar to that observed in
women with recent hip fracture [63]. Low numbers of clinical fractures
were observed in men in the HORIZON-RFT (16 [7.45%] and 20 [8.7%]
for zoledronic acid and placebo, respectively), with no signiﬁcant differ-
ence between the treatment groups. This lack of a statistically signiﬁcant
fracture reduction was expected, as the gender-based subset analysis
was powered for a BMD endpoint and not for anti-fracture efﬁcacy. In
line with these ﬁndings, a head-to-head trial comparing once-yearly
zoledronic acid with daily oral alendronate in men with low BMD also
showed the expected effects of zoledronic acid on bone density and
bone turnover [64].
Most recently, a fracture endpoint study in male osteoporosis inves-
tigated once-yearly intravenous (iv) zoledronic acid treatment in a
randomised, multi-centre, double-blind, placebo-controlled, two year
study. Theprimary efﬁcacy endpointwas the reduction in vertebral frac-
ture risk at the two-year endpoint of the trial. In all, 1199 patients were
randomised to an annual infusion of either zoledronic acid 5 mg or pla-
cebo, and supplemented with calcium 1000–1500 mg and vitamin D
800–1200 mg/day. Patient inclusion and exclusion criteria were similar
to previous bisphosphonate studies, in that men aged 50–85 years
(mean age 65.8) with primary osteoporosis or secondary osteoporosis
due to hypogonadismwere included. Of note, this was a low-risk popu-
lation compared to studies investigating postmenopausal women on
zoledronic acid, because male reference values were used. The results
of the study have recently been fully published [65]. Overall, theﬁndings
showed changes in surrogate outcomes (bone density and bone turn-
over) in line with those reported in pivotal trials of postmenopausal
women [66]. Vertebral fracture risk reductions were similar in magni-
tude to those previously reported with iv zoledronic acid in postmeno-
pausal osteoporosis.
Teriparatide
Teriparatide is classiﬁed as a parathyroid hormone (PTH) analogue
that has an identical sequence to the 34 N-terminal amino acids
(the biologically active region) of the 84-amino acid humanparathyroid
hormone. It is indicated to increase bone mass in men with primary orhypogonadal osteoporosis at high risk for fracture and in the treatment
of osteoporosis associated with sustained systemic glucocorticoid
therapy in men at high risk of fracture.
Teriparatide monotherapy
Initial indications that teriparatide was useful in male osteoporosis
were published in the 1980s [67,68]. A placebo-controlled, double-blind
trial subsequently led to its approval for the treatment of men in the US
[69] (Table 3). This bridging study included 437 men with low BMD
(hip or spine T-score b−2.0 SD) without secondary causes of osteoporo-
sis. Patients were randomised into three groups, and either received once
daily subcutaneous 20 or 40 mcg teriparatide, or placebo. The patients
were supplemented with calcium (1000 mg/day) and vitamin D (400
to 1200 IU) (continued during the subsequent follow-up observation
phase). The study's primary endpoint was lumbar spine BMD. It was pre-
maturely terminated (median total exposure 11 months), because osteo-
sarcomas developed in rats during toxicological evaluation. This
observation was, however, not considered predictive of an increased
risk for humans treated for relatively short periods [70]. Baseline values
showed that the study population was relatively young (58–59 years
old), with relatively elevated spine BMD and low risk T-scores. About
40% of participants had vertebral fractures and half had low free testos-
terone values.
The patterns of biochemical marker changes in response to
teriparatide were typical (dose-dependent increases in bone formation
and resorption markers) and very closely mirrored similar data in
women, albeit with a lower magnitude [69]. The changes in BMD were
also very similar to those previously reported in women [71]. Both
teriparatide doses led to the expected changes in spine, total hip and
femoral neck BMD. When BMD responses to 20 mcg of teriparatide
are compared in men and women, the absolute change in BMD is simi-
lar. Analyses showed consistent responses across the risk groups usually
seen in male osteoporosis, in that responses did not differ according to
baseline BMD, age, gonadal status, previous fracture status, smoking or
alcohol consumption [69].
In an 18-month follow-up study, about 80% of patients agreed to be
observedwithout receiving studymedication, butwith the option to un-
dertake other therapies [72]. After treatment discontinuation, BMD de-
clined in both teriparatide treatment groups, particularly at the lumbar
spine [72]. There was no difference in the rate of BMD decline as a func-
tion of testosterone concentrations [72]. From the original treatment
trial baseline to the 18 months visit of the follow-up study, there was a
lower incidence of moderate and severe fractures, in the combined 20
and 40 mcg teriparatide groups than in the placebo group (p=0.01)
[72]. However, these data should be interpreted with caution, because
approximately 22% of the men reported the use of a bisphosphonate at
some point during the follow-up study. Again, the point estimates for
the reduction in vertebral fracture risk in men were essentially the
same as in women [73], despite the smaller study size.
Of interest, Leder et al. investigated the effects of teriparatide
treatment and discontinuation [74] in a small study involving 14
postmenopausal women and 17 eugonadal men with osteoporosis,
aged 46–85 years, with lumbar spine or femoral neck T-scores b−2
SD. Daily teriparatide (37 mcg) was administered subcutaneously for
24 months, followed by 12 months off therapy. The study observed
that, following teriparatide discontinuation, the rate of BMD decline
was greater in women than in men, possibly highlighting a difference
in teriparatide response or in the drivers of BMD maintenance in men
and women. The 5.9% female to male difference in trabecular BMD
loss was statistically signiﬁcant (p=0.037; 95% CI, 11.2–0.4), but the
difference in absolute trabecular BMD loss was not. The mechanisms
underlying this potential relative resistance to post-teriparatide bone
loss inmen are unclear. This observation requires conﬁrmation in larger
studies and in men and women receiving the approved teriparatide
dose of 20 mcg/day. One concern is that teriparatide appears to require
continued administration for a sustained biological effect, unlike
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months after drug exposure [75–77]. However, Lindsay et al. also
reported that women with postmenopausal osteoporosis showed
sustained vertebral fracture risk reduction after withdrawal of
teriparatide (at least 18 months) [73].
Finally, a post-marketing study on the use of teriparatide in the US,
derived from the Direct Assessment of Nonvertebral Fracture in the
Community Experience (DANCE) study, described gender differences
for initiating teriparatide therapy. The drug was used more often in
women, based on general frailty, low body mass and an inadequate re-
sponse or intolerance to previous therapy. Chronic glucocorticoid ther-
apy was the reason most often given by investigators for initiating
therapy in men, and more often used as an indicator for therapy in
men, illustrating the possibility that at least in the US, physicians view
teriparatide use somewhat differently in men vs. women [78], and
providing further evidence from a clinical practice setting that male
osteoporosis is under-diagnosed and likely under-treated.Teriparatide combination therapy
A study randomly assigned 83 men with low BMD to receive
10 mg/day alendronate, 40 mcg/day teriparatide subcutaneously, or
both. Alendronate was administered for 30 months, and teriparatide
was started after six months. Lumbar spine and femoral neck BMD in-
creased signiﬁcantly more in men on teriparatide monotherapy com-
pared with the other groups. Changes in serum BTM were signiﬁcantly
greater in the teriparatide group than in the alendronate group or the
combination therapy group (pb0.001). As with BMD, a second study
showed that alendronate impaired the action of teriparatide to increase
bone turnover in men [79,80]. Previous studies in postmenopausal
women also suggested that concomitant alendronate and PTH (1–84)
reduced the anabolic effects of PTH [75,81]. These data may inﬂuence
therapeutic choices after PTH discontinuation, because its use is limited
to a maximum of two years [75].
Although these studies suggested that combination of teriparatide
and bisphosphonates had no additive effect because alendronate dimin-
ished the teriparatide effect, zoledronic acidwas shown not to block the
anabolic effect of PTH. In a one-year partial double-blind randomised
study of 412 postmenopausal women, Cosman et al. concluded that,
while teriparatide increased spine BMD more than zoledronic acid,
and zoledronic acid increased hip BMD more than teriparatide, combi-
nation therapy provided the best BMD improvement, both in spine
and hip BMD [82].Available treatments for osteoporosis in men: conclusions and discussion
The treatment response to oral bisphosphonates in male osteopo-
rosis is similar to that observed in postmenopausal osteoporosis, in
terms of bone density and bone remodelling. To date, conclusive
anti-fracture evidence with alendronate and risedronate is unavailable
in men, but fracture reductions are very consistent. With iv zoledronic
acid, a recent report of fracture endpoint data in osteoporotic men indi-
cates that zoledronic acid anti-fracture efﬁcacy in men mirrored that
observed in women. The approaches developed to treat and identify
women at high risk (e.g. the FRAX approach) are likely to be equally
useful in men.
Teriparatide studies concluded that the changes in biochemical
markers, BMD, and vertebral fracture risk in response to 20 mcg
teriparatide in men were essentially the same as in women. Studies
have suggested that combination of teriparatide and alendronate di-
minished the teriparatide effect, but zoledronic acid was shown not to
block the anabolic effect of PTH in women. Teriparatide appears to
be an effective therapy in men with osteoporosis, yet maintenance
of its effects after treatment cessation is not fully understood and
may require subsequent initiation of bisphosphonate treatment.Sex hormones
Several agents are known to have a positive effect on BMD in the
extreme event of acute hypogonadism due to chemical castration, in-
cluding bisphosphonates and denosumab (discussed below) [83,84].
It seems reasonable to use these agents to avoid bone loss in men re-
ceiving androgen deprivation therapy, particularly when baseline
BMD is low or if other fracture risk factors are present.
Testosterone prevents bone loss and may increase bone mass in
hypogonadal men, although there is little available long-term data
and no fracture data. Despite testosterone's beneﬁcial effects on the
skeleton when initiated in the broader context of androgen replacement
in established hypogonadism, it is not indicated for osteoporosis treat-
ment as such [9]. A hypogonadal man with a high risk of fracture should
receive classical osteoporosis medication [58], regardless of whether
testosterone is being initiated on the basis of current hypogonadism
treatment guidelines.
An important point concerns oestradiol, which may be more related
to fracture than testosterone, and raises the question of oestradiol assay
sensitivity and standardisation. Low oestradiol levels were associated
with high bone remodelling and bone loss, whereas no such relationship
was found for testosterone [85,86], and were also associated with in-
creased fracture incidence [87]. In the MrOs cohort, sex steroids were
measured usingmass spectrometry in elderlymen. Serum-free oestradiol
but not testosterone, was independently associated with fracture risk
[88]. In clinical practice, the potential implication is that measurement
of serum sex steroid contribution could become standardised. These
data provide a rationale for assessing the use of selective oestrogen recep-
tor modulators (SERMs) in men. Although oestrogen or SERMs are cur-
rently not approved for use in men, raloxifene reduces bone turnover in
men with low endogenous oestradiol levels [89,90] and increases BMD
in prostate cancer patients undergoing gonadal suppression therapy
[91], with the caveat that raloxifene increases bone turnover in men
with serum oestradiol levels above the population median.
Agents in development for men
A number of drugs with anti-fracture efﬁcacy in postmenopausal
women are available and are likely to be applicable in men, provided
that bridging studies are carried out. An overview of drugs in develop-
ment demonstrates that the most promising novel treatments include
combination treatments (as outlined above with bisphosphonates and
teriparatide), denosumab, strontium ranelate, odanacatib (a speciﬁc in-
hibitor of the osteoclast protease cathepsin K), antibodies against endog-
enous inhibitors of bone formation sclerostin and dickkopf-1 (Dkk-1),
and saracatinib (Src inhibitor), a cancer drugwhich has not yet been ap-
plied in osteoporosis (reviewed in [92]).
Therapies in late-stage development
Denosumab
The anti-resorptive denosumab is a monoclonal antibody that binds
and neutralises the activity of human receptor activator of nuclear
factor-κB ligand (RANKL), a key osteoclast cytokine, similarly to endog-
enous osteoprotegerin. This agent is indicated to increase bone mass in
men at high risk for fracture receiving androgen deprivation therapy for
nonmetastatic prostate cancer. Denosumab has been shown to increase
BMDand reduce fractures in postmenopausalwomenwith osteoporosis
[93] and inmenwith prostate cancer on hormone ablation therapy. In a
double-blind, randomised, multi-centre study, denosumab was investi-
gated inmen receiving androgen-deprivation therapy for nonmetastatic
prostate cancer. Patients received 60 mg denosumab subcutaneously
every sixmonths or placebo (734patients in each group). At 24 months,
lumbar spine BMD increased by 5.6% in the denosumab group as com-
pared with a loss of 1.0% in the placebo group (pb0.001). The difference
was signiﬁcant as early as one month. Signiﬁcant BMD increases were
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at all time points. At 36 months, denosumab-treated patients had a sig-
niﬁcantly decreased incidence of new vertebral fractures (1.5%, vs. 3.9%
with placebo) (RR, 0.38; 95% CI, 0.19–0.78; p=0.006), and markers of
bone turnover were signiﬁcantly decreased compared with placebo
(pb0.001) [84]. The efﬁcacy and safety of denosumab in men with low
bone mass at risk of fracture is being further evaluated in the ongoing
phase III denosumab vs. placebo ADAMO trial [94].
Strontium ranelate
Strontium ranelate is an alternative orally active drug with opposite
effects on bone resorption and formation, that has been demonstrated
to signiﬁcantly reduce vertebral and non-vertebral fracture risk in
womenwithpostmenopausal osteoporosis [95,96]. At timeof submission
of this review, Strontium ranelatewas recently approved for treatment of
osteoporosis in men, but the complete results of the main study in men
have not yet been published. A two-year, controlled, double-blind bridg-
ing study has been performed in osteoporotic men. The objective was to
studymenwith a similar risk proﬁle as the postmenopausal women pre-
viously included in the pivotal phase 3 trials, therefore the BMD inclusion
criterion was below a same absolute BMD threshold value as in the stud-
ies in women. In a preliminary communication of the results at one year
(main study analysis), the authors reported that a same dosage of stron-
tium ranelate with calcium and vitamin D supplementation resulted in
similar strontium blood levels and a similar signiﬁcant BMD gain at the
spine and hip in osteoporoticmen comparedwith osteoporotic postmen-
opausal women [97].
Of note, an open-label, prospective, controlled, BMD endpoint
12-month trial in male osteoporosis patients compared strontium
ranelate 2 g/day (n=76) vs. alendronate 70 mg/week, an agent already
approved for male osteoporosis. Mean increases in lumbar spine and
total hip BMD were greater with strontium ranelate compared with
alendronate [98], although the increment in BMD is partly dependent
on a treatment-induced artefact. These strontium ranelate data support
the increases in BMD observed in the recent core bridging study.
Odanacatib
Odanacatib inhibits cathepsin-K, a protease that plays an important
part in osteoclast function. A phase III odanacatib trial inmenwith osteo-
porosis is ongoing (NCT01120600). In postmenopausalwomen, the effect
of odanacatib on biochemical markers of bone turnover (sCTX, bALP) and
on change in lumbar spine and femoral neck BMD (vs. baseline) was
promising at 24 and 36 months [99,100]. Femoral neck BMD decreased
after odanacatib discontinuation, although it remained above baseline
levels [100].
Therapies in early-stage development
Sclerostin inhibitors
Therapies currently in phase II development include sclerostin in-
hibitors [101]. Data obtained in sclerostin knock-out (KO) mice have
shown that these have high bone mass and normal bone morphology,
but with increased trabecular and cortical bone volume. Other than
the bone phenotype, no additional biologically signiﬁcant differences
were observed between wild-type and KO mice. Based on micro CT
imaging, female KO mice appeared to have increased bone volume
compared with males [102]. Anti-sclerostin antibody was also
shown to increase markers of bone formation and BMD in healthy
men and postmenopausal women [103].
Calcilytics
The stimulation of spontaneous endogenous PTH secretion, using
calcium receptor agonists that tend to reduce serum calcium (calcilytics),
has been proposed as an alternative approach to teriparatide administra-
tion. Examples of such compounds include ronalcaleret and JTT-305.
Ronalcaleret had no effect on BMD, possibly because of a prolongedstimulation of PTH secretion [104]. JTT-305was tested over threemonths
in 154 postmenopausal osteoporotic women randomised to three
groups: placebo (n=51), 10 mg/day (n=50) and 20 mg/day (n=53).
Some differences in spine BMD and effects on P1NP and CTX markers,
were found [105]. Interesting data on newer calcilytic drugs may emerge
in the near future [92].
Drugs in pre-clinical development
Wnt/beta-catenin pathway
Advances in themolecular understanding of processes involved in the
bone-anabolic pathwayhavehighlighted the canonicalWnt/beta-catenin
pathway as a key regulator of bone formation [106], which is negatively
regulated by Wnt inhibitors such as Dkk-1 and sclerostin [107]. The
Wnt pathway is composed of multiple potential drug targets involved
in its activation (19 Wnts, 10 Frizzled, 3 LRPs) or inhibition (4 Sfrp,
Dkk-1, sclerostin). Some components such as catenin, Rho, or PKC also
interact with multiple pathways that are not speciﬁc for bone, which
complicates matters in the context of targeted therapy. Importantly, in-
terference with Wnt inhibitory factor 1 (WIF1) is associated with a po-
tential risk of neoplastic development (osteosarcoma) [108]. Moreover,
the reversibility or duration of the effect is not fully established. If therapy
is stopped once good bone forming activity has been achieved, it is not
clear whether this effect should be maintained with the administration
of bone resorption inhibitors.
Selective androgen receptor modulators
Selective androgen receptor modulators (SARMs) have been shown
to improvemuscle strength and body composition, and to prevent bone
loss in orchidectomised rats [109]. These agents display tissue-selective
pharmacologic activity and may have an advantage over steroidal an-
drogen therapy. Yarrow et al. demonstrated that trenbolone had advan-
tages over testosterone in orchidectomised rats, supporting the need for
future studies examining its potential in androgen replacement therapy
[110]. Overall, these data do not display a very high magnitude of effect
on bone strength. Moreover, the effects of respective SARMs on endog-
enous oestrogen levels and on the skeleton may diminish the clinical
potential of these agents [9].
Agents in development for men: conclusions and discussion
Potential drugs for the treatment of osteoporosis inmen include two
broad categories, either of bone resorption inhibitors or of bone forma-
tion stimulators, as reviewed elsewhere [92]. Several additional agents
are expected to be approved for the treatment of osteoporosis in men
in the near future. Strontium ranelate has recently been approved
in Europe for treatment of osteoporosis in men, but publication of
complete results of the core study is still awaited. Denosumab is ap-
proved for use in men receiving androgen deprivation therapy for
nonmetastatic prostate cancer who are at high risk of fracture. Data on
the effect of denosumab in men with low bone mass at risk of fracture
are also on the horizon. Other promising therapies at different stages of
development include odanacatib, sclerostin inhibitors, or calcilytics.
Overall discussion and conclusions: who should be treated?
There is general agreement on the diagnosis of osteoporosis in men.
In termsof assessment algorithms, different approaches have been used,
either a traditional approach or a fracture probability-based approach,
as is the case in the UK (Table 2). FRAX is, however, increasingly used
in guidelines as they undergo revision.
The treatment algorithm and clinical guidance, which this panel
wishes to support, aim to treat men at a similar 10-year fracture risk
as in women, because the morbidity and mortality associated with
major osteoporotic fractures in men are substantial. Available evidence
suggests that treatment algorithms in women are also applicable to
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factors (Table 1). The use of ﬁxed intervention thresholds is viewed as
counter-intuitive to current practice, because the risk is to exclude too
many younger patients and, conversely, to include too many older
patients above a threshold value.
The available level of evidence that treatment decreases the risk of
fracture in men is lower than for women. As such, the US Endocrine So-
ciety is of the opinion that there is currently not enough information in
men to make a recommendation, because too few fractures have been
recorded in men to link BMD changes with anti-fracture efﬁcacy. Addi-
tional fracture data are needed to endorse the clinical care of osteoporosis
in men. However, this panel believes that this view can be countered,
based on available epidemiological and clinical efﬁcacy data in male sub-
jects, which display similarities with data acquired inwomen, in terms of
treatment effects on BMD, biochemical markers of bone turnover, and
fracture endpoint, despite the recorded differences in pathophysiology
of bone loss and bone microarchitecture. Overall, empirical data from
men and women are so similar that differences in morphology may not
be clinically relevant.
Despite the wealth of available data from numerous studies in
women, the current strategy of drug development for the treatment of
osteoporosis in men is such that there is a delay of several years before
clinical trial data in men become available. Perhaps the lag between
comparable treatments becoming available for female and for male os-
teoporosis can be reduced. The situation is not unlike coronary artery
disease, which was initially thought to be principally a male disease,
but for which female treatment was made more rapidly available. A
logical conclusion would eventually be to design mixed studies, as
recommended by the WHO [111]. From a pragmatic point of view,
it is unlikely that drugs for the speciﬁc treatment of osteoporosis in
men will be developed.
One area of research that deserves more attention is the hormonal
and non-hormonal factors inﬂuencing bone loss in men. There ap-
pears to be potential in measuring serum oestradiol levels, in addition
to testosterone levels in men with low BMD. We wish to encourage
the development of standardised mass spectroscopy assays for the as-
sessment of sex steroid contribution in male osteoporosis.
Awareness of osteoporosis in men is improving, although it remains
under-diagnosed and under-treated. It is important to highlight this
population of patients and to deﬁne treatment options and intervention
strategies, in order to reduce mortality, improve treatment and care,
and make sure that treatments reach those who most need it.
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